latest news from cognivia

268

Link to full article Multiple gene alterations and insertions to CA3 hippocampal neurones demonstrated in vivo with 99.8% success rate.

Link to full article Study shows second-generation Mnemosyne (MNS) provides significantly greater event recall improvement than other market drugs.

Link to full article Cognivia acquires 51% stake in Agilon AI.

Link to full article Cognivia - Board and Directorate changes.

Link to full article New drug application submitted to Perplex City authorities for in situ production of CNS boosters.

267

Link to full article Online science exhibit wins Perplex City Understanding award - exhibit recognised for helping students learn about medical imaging and diagnostics.

Link to full article Cognivia grants a voluntary licence for generic production and sale of second-generation Ceretin.

Link to full article New data shows new Halcyon delivers rapid onset of action and lasting anxiolytic effect with reduced side-effects.

Link to full article Cognivia responds to Academy Cognitive Enhancement Advisory Committee recommendations on use of analytical and systemising enhancers in mission-critical situations.

Link to full article 264 winner of the Academy Games joins Cognivia's 'Understanding the Senescence Problem' team.

Link to full article New survey provides insights into unique relationship between teachers, students and cognitive psychologists.

Link to full article Keynote presentation by Cognivia CEO at the Fourth Cerebral Prostheses Conference.

Link to full article Cognivia updates publicly accessible database on clinical-trial information.

Link to full article Cognivia ranked first in Perplex City 100 list.

archives

Full archives of Cognivia news are currently not accessible.